Title
The growth inhibiting effect of docetaxel (Taxotere®) in head and neck squamous cell carcinoma xenografts
Author
Medisch Biologisch Laboratorium TNO
Braakhuis, B.J.M.
Kegel, A.
Welters, M.J.P.
Publication year
1994
Abstract
Docetaxel (Taxotere®) is a new antitumor agent with activity in patients with ovarian, lung and breast cancer. In this study, docetaxel was tested for its antitumor effect in human tumor xenografts derived from head and neck squamous cell carcinoma (HNSCC). A significant growth inhibiting effect was observed in the two tested lines, at the well tolerated dose of 20 m/kg docetaxel. Two intravenous injections were given with a week interval. Both lines were less sensitive to treatment with cisplatin, indicating that no cross-reactivity exists between these drugs. Docetaxel has a promising outlook in the treatment of patients with head and neck squamous cell carcinoma (HNSCC). Chemicals/CAS: Antineoplastic Agents, Phytogenic; Cisplatin, 15663-27-1; docetaxel, 114977-28-5; Paclitaxel, 33069-62-4
Subject
Antitumor effect
Docetaxel
Head and neck cancer
Squamous cell carcinoma
Taxol
Taxotere®
antineoplastic agent
cisplatin
docetaxel
animal experiment
animal model
article
cancer inhibition
cell growth
controlled study
drug cross reactivity
female
head cancer
intravenous drug administration
mouse
neck cancer
nonhuman
priority journal
squamous cell
squamous cell carcinoma
tumor xenograft
Animal
Antineoplastic Agents, Phytogenic
Carcinoma, Squamous Cell
Cell Line
Cisplatin
Comparative Study
Female
Head and Neck Neoplasms
Human
Mice
Mice, Nude
Neoplasm Transplantation
Paclitaxel
Support, Non-U.S. Gov't
To reference this document use:
http://resolver.tudelft.nl/uuid:70eb0666-09b0-4acb-9569-e0786588d974
DOI
https://doi.org/10.1016/0304-3835(94)90196-1
TNO identifier
232638
ISSN
0304-3835
Source
Cancer Letters, 81 (81), 151-154
Document type
article